Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Knappertz

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|August 9, 2006
The dose of aspirin for the prevention of cardiovascular and cerebrovascular eventsMatt Fisher, Volker Knappertz
The American Journal of Medicine|February 24, 2006
Comments in response to "low-dose aspirin increases aspirin resistance in patients with coronary artery disease"Matt Fisher, Volker Knappertz
The American Journal of Cardiology|November 9, 2005
Comments in response to "Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials"Matt Fisher, Volker Knappertz
European Heart Journal|June 6, 2006
Aspirin and clopidogrel resistance: an emerging clinical entityAnthony Johns, Matt Fisher, Volker Knappertz
Medical Device Technology|January 12, 2010
Needles: a comparison studyGerhard Mayer, Volker Knappertz, Peter Kinast
American Heart Journal|July 1, 2008
An assessment of the joint associations of aspirin and statin use with C-reactive protein concentrationMatt Fisher, Mary Cushman, Volker Knappertz, et al.
BMC Neurology|September 19, 2016
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagreeGary R Cutter, Volker Knappertz, Nissim Sasson, et al.
Clinical Pharmacology and Therapeutics|October 6, 2020
Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical TrialPaul B Watkins, Rachel J Church, Jie Li, et al.
Expert Opinion on Drug Safety|December 20, 2016
Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosisTjalf Ziemssen, Natalia Ashtamker, Svetlana Rubinchick, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 18, 2017
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA studyMat D Davis, Natalia Ashtamker, Joshua R Steinerman, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|August 9, 2006
The dose of aspirin for the prevention of cardiovascular and cerebrovascular eventsMatt Fisher, Volker Knappertz
The American Journal of Medicine|February 24, 2006
Comments in response to "low-dose aspirin increases aspirin resistance in patients with coronary artery disease"Matt Fisher, Volker Knappertz
The American Journal of Cardiology|November 9, 2005
Comments in response to "Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials"Matt Fisher, Volker Knappertz
European Heart Journal|June 6, 2006
Aspirin and clopidogrel resistance: an emerging clinical entityAnthony Johns, Matt Fisher, Volker Knappertz
Medical Device Technology|January 12, 2010
Needles: a comparison studyGerhard Mayer, Volker Knappertz, Peter Kinast
American Heart Journal|July 1, 2008
An assessment of the joint associations of aspirin and statin use with C-reactive protein concentrationMatt Fisher, Mary Cushman, Volker Knappertz, et al.
BMC Neurology|September 19, 2016
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagreeGary R Cutter, Volker Knappertz, Nissim Sasson, et al.
Clinical Pharmacology and Therapeutics|October 6, 2020
Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical TrialPaul B Watkins, Rachel J Church, Jie Li, et al.
Expert Opinion on Drug Safety|December 20, 2016
Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosisTjalf Ziemssen, Natalia Ashtamker, Svetlana Rubinchick, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 18, 2017
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA studyMat D Davis, Natalia Ashtamker, Joshua R Steinerman, et al.
Pageof 5